Metastasectomy for Stage IVA Colon Cancer: Does the Type of Treating Institution Make a Difference?. Issue 8 (August 2022)

• Record Type: Journal Article
• Authors: Kang, Shinho T.; Moran, Ryan; Hussain, Lala; Guend, Hamza; Dunki-Jacobs, Erik M.; Lee, David Y.
• Is Part Of: American surgeon. Volume 88:Issue 8(2022)
• Page Start: 1976
• Page End: 1982
• Publication Date: 2022-08
• Subjects: metastatic colon cancer -- metastasectomy -- stage IVA colon cancer -- isolated liver metastasis -- chemotherapy -- liver resection -- community -- comprehensive community -- academic -- research -- integrated cancer network -- neoadjuvant therapy; Surgery -- Periodicals; Surgery -- United States -- Periodicals; 617.0973
• DOI: 10.1177/00031348211023389
• Languages: English
• ISSNs: 0003-1348

Abstract

Treatment of metastatic colon cancer has evolved over time. More evidence has been emerging in recent years supporting metastasectomy in selected patients. We sought to elucidate whether the type of institution—community, comprehensive community, academic/research, and integrated cancer network—would have an effect on patient outcome, specifically those colon cancer patients with isolated liver metastasis. This retrospective cohort study queried the National Cancer Database (NCDB) from 2010 to 2014 for patients who were 18 years of age or older with stage IVA colon cancer with isolated liver metastasis. We then performed uni- and multivariate analyses comparing patients based on such factors as age, tumor characteristics, primary tumor location, rate of chemotherapy, and type of treating institution. Patients who came from regions of higher income, receiving chemotherapy, and presenting to an academic/research hospital were more likely to undergo metastasectomy. Median survival was longest at academic/community hospitals at 22.4 months, 6 to 7 months longer than the other three types of institutions. Factors positively affecting survival included receiving chemotherapy, presenting to an academic/research institution, and undergoing metastasectomy, all at P < .05. In our study, the rate of metastasectomy was more than double at academic/research institutions for those with stage IVA colon cancer with isolated liver metastasis. Prior studies have quoted a mere 4.1% synchronous colon resection and metastasectomy. Our findings suggest that we should maintain multidisciplinary approach to this complex disease process and that perhaps it is time for us to consider regionalization of care in treating metastatic colon cancer.